SILVER SPRING, Md., April 10, 2013 /PRNewswire/ -- Pharmagen, Inc. (OTCBB: PHRX) (the "Company" or "Pharmagen") is excited to announce that it has entered into an agreement to use proprietary ScanRDI technology from BioMerieux. Pharmagen Laboratories is only one of five sterile compounding companies in the United States to use ScanRDI, a cutting edge technology that reduces the method time for product sterility testing from 14 days to less than 3 hours. Utilizing solid phase cytometry in conjunction with fluorescent viability staining, ScanRDI allows for product sterility results in a matter of minutes. This is the only technology in the world that can detect contamination down to one viable microorganism without the need for growth or enrichment. While most compounding companies randomly skip-lot test, Pharmagen Laboratories tests every lot, every time. With this new, unparalleled turnaround time, Pharmagen can now produce new compounds in a matter of hours – giving the company an enormous competitive advantage in responding to an ever-changing market place.
"Patient safety in compounding has become a hot topic after New England Compounding Center's meningitis outbreak and there isn't another company out there that takes it as seriously as we do. Pharmagen has passed recent FDA and State Board of Pharmacy inspections, in addition to hiring an industry leading consulting firm, Kymanox, for an independent review. Taking lessons from the pharmaceutical manufacturing space, we're instituting cutting edge Standard Operating Procedures, and as many USP and cGMP guidelines as we can in a compounding environment. We see competitors testing a small percentage of what leaves their facilities. Products from typical compounding facilities are shipped prior to having test results in hand, resulting in recalls on an almost daily basis. Pharmagen tests absolutely everything we produce and nothing leaves our facility until we know it's safe," said Mackie A. Barch, CEO of Pharmagen.
"Additionally, the demands of the health provider market are extremely dynamic. Being able to save two weeks give us a real advantage because two weeks is a lifetime in this business – both for us and the patients we ultimately serve," continued Barch.